Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in TP53-Aberrant Triple-Negative Breast Cancer

BACKGROUND: In triple-negative breast cancer (TNBC), PDL1/PD1-directed immunotherapy is effective in less than 20% of patients. In our preliminary study, we have found CSPG4 to be highly expressed together with PDL1 in TNBCs, particularly those harboring TP53 aberrations. However, the clinical impli...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Zhe-Yu, Zheng, Chanjuan, Yang, Jianbo, Ding, Siyu, Tian, Can, Xie, Ning, Xue, Lian, Wu, Muyao, Fu, Shujun, Rao, Zhouzhou, Price, Matthew A., McCarthy, James B., Ouyang, Quchang, Lin, Jizhen, Deng, Xiyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907582/
https://www.ncbi.nlm.nih.gov/pubmed/35280756
http://dx.doi.org/10.3389/fonc.2022.804466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907582/
https://www.ncbi.nlm.nih.gov/pubmed/35280756
http://dx.doi.org/10.3389/fonc.2022.804466

Ejemplares similares